<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880643</url>
  </required_header>
  <id_info>
    <org_study_id>2018/1509</org_study_id>
    <nct_id>NCT03880643</nct_id>
  </id_info>
  <brief_title>Rituximab in Refractory Primary Membranous Nephropathy</brief_title>
  <official_title>Efficacy and Safety of Rituximab in Patients With Refractory Primary Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary membranous nephropathy (PMN), an autoimmune disease mostly associated with
      anti-phospholipase-A2-receptor (PLA2R) antibodies, is one of the most common causes of
      nephrotic syndrome in adults. In 30% to 40% of all cases, patients with PMN undergo
      spontaneous remission with conservative approaches. Corticosteroids, alkylating agents and
      calcineurin inhibitors are recommended treatment options in persistent disease activity
      despite supportive therapies. Nevertheless, patients with refractory disease constitute an
      important clinical aspect of PMN, and uncontrolled proteinuria may culminate in rapid
      progression to end-stage renal disease. In recent years, several studies demonstrated the
      efficacy of rituximab as a treatment option in patients with refractory PMN; however, data
      regarding daily clinical practice of this agent is still needed. Therefore, we conducted a
      study using our registry data to evaluate the efficacy and safety of rituximab in patients
      with refractory PMN.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>6 months</time_frame>
    <description>Proteinuria &lt;0.3 g/day, confirmed by two values at least 1 week apart, accompanied by a normal serum albumin concentration, and a normal serum creatinine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial Remission</measure>
    <time_frame>6 months</time_frame>
    <description>Proteinuria &lt;3.5 g/day and a 50% or greater reduction from peak values, confirmed by two values at least 1 week apart, accompanied by an improvement or normalization of the serum albumin concentration and stable serum creatinine.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Glomerulonephritis, Membranous</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Patients with primary membranous nephropathy who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to at least one set of prior therapies including corticosteroids, alkylating agents or calcineurin inhibitors.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary membranous nephropathy who were treated using rituximab following
        resistance to at least one set of prior therapies including corticosteroids, alkylating
        agents or calcineurin inhibitors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having biopsy-proven primary membranous nephropathy.

          -  Showing resistance to at least one set of prior therapies including corticosteroids,
             alkylating agents or calcineurin inhibitors.

          -  Having a history of rituximab use (375 mg/m2/wk for 2-4 weeks) following resistance
             aforementioned agents.

        Exclusion Criteria:

          -  Not providing or withdrawing consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halil Yazici, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Safak Mirioglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27.</citation>
    <PMID>27352623</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Safak Mirioglu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>membranous nephropathy</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

